Skip to content

Effect of Plasma Sodium Concentration on Blood Pressure Regulators During Hemodialysis

Is the Lower Incidence of Intradialytic Hypotension During Hemocontrol Dialysis in Comparison With Standard Hemodialysis Attributable to Enhanced to Higher Plasma Vasopressin Levels or to Enhanced Sympathetic Activity and/or to Less Nitric Oxide Production

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03578510
Enrollment
29
Registered
2018-07-06
Start date
2012-09-17
Completion date
2013-03-25
Last updated
2023-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients With End Stage Renal Disease on Hemodialysis

Keywords

Hemodialysis, sodium, endothelium, sympathetic activity, vasopressin

Brief summary

Intradialytic hypotension (IDH) is a frequent and serious complication that may occur during hemodialysis treatment. The investigators and others have shown that the Hemocontrol biofeedback system is associated with improved hemodynamic stability. Hemocontrol is a technique that guides the patients' blood volume along a pre-set trajectory by continuously adjusting the ultrafiltration rate and dialysate conductivity. In a recent pilotstudy, the investigators found significantly higher plasma vasopressin levels during the first hour of dialysis with Hemocontrol in comparison with standard hemodialysis. Increased vasopressin levels may contribute to intradialytic hemodynamic stability during hemodialysis by enhanced vasoconstriction. These results, however, did not prove directly that the improved hemodynamic stability with Hemocontrol is indeed caused by higher initial plasma vasopressin levels. Alternative explanations might be that 1) the higher initial plasma sodium levels with Hemocontrol dialysis enhance activity of the sympathetic nervous system directly, causing vasoconstriction and thereby improved hemodynamic stability and/or 2) that the higher initial plasma levels of sodium in Hemocontrol inhibit the release of nitric oxide by the vascular endothelium. Another goal of this study is to investigate whether vasopressin is removed with hemodialysis.

Interventions

DEVICEHemocontrol hemodialysis

Each participating patient underwent one standard hemodialysis and one hemodialysis with Hemocontrol in random order, both 4 hours in total duration. The Hemocontrol system guides the patients' blood volume along a predefined ideal relative blood volume trajectory, by continuously adjusting ultrafiltration volume and dialysate sodium concentration.

Each participating patient underwent one standard hemodialysis and one hemodialysis with Hemocontrol in random order, both 4 hours in total duration. During standard hemodialysis, a constant ultrafiltration rate and dialysate conductivity was used.

Sponsors

University Medical Center Groningen
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Age ≥18 years * A thrice-weekly 4 hours hemodialysis schedule * Dialysis on an arteriovenous fistula * A usual interdialytic weight gain of ≥2.0 kg

Exclusion criteria

* Age\<18 years * Dialysis duration of \<4 or \>4 hours * Dialysis frequency of \<3 or \>3 times a week * Dialysis on a central venous catheter * A usual interdialytic weight gain \<2 kg

Design outcomes

Primary

MeasureTime frameDescription
Change in plasma vasopressin levelsBefore, after 30, 60, 120 and 180 minutes and after dialysis blood is withdrawn from the dialysis line to determine plasma levels of vasopressin.Plasma levels of the antidiuretic hormone, i.e. vasopressin

Secondary

MeasureTime frame
Change in heart rate in beats per minuteBefore, after 30, 60, 120 and 180 minutes and after dialysis
Change in relative blood volume in %Before, after 30, 60, 120 and 180 minutes and after dialysis
Change in systolic and diastolic blood pressure in mmHgBefore, after 30, 60, 120 and 180 minutes and after dialysis
Change in plasma sodium levels in mmol/LBefore, after 30, 60, 120 and 180 minutes and after dialysis

Other

MeasureTime frame
Change in plasma osmolality levels in milliosmol/kgBefore, after 30, 60, 120 and 180 minutes and after dialysis
Change in nitrite and nitrate levels in µmol/LBefore, after 30, 60, 120 and 180 minutes and after dialysis
Change in plasma noradrenalin levels in mmol/LBefore, after 30, 60, 120 and 180 minutes and after dialysis
Change in heart rate variability in msBefore, after 30, 60, 120 and 180 minutes and after dialysis
Change in baroreflex sensitivity in ms/mmHgBefore, after 30, 60, 120 and 180 minutes and after dialysis

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 5, 2026